The earnings call highlighted PureTech's strong cash position and operational efficiency, progress in core founded entities, and strategic financing with promising valuation for Seaport Therapeutics. However, there are challenges with the need for ongoing external financing for core entities and leadership transitions. The overall sentiment is balanced with strong positive aspects but also significant challenges.

Company Guidance

During the PureTech Health 2025 Half Year Earnings Webcast, the company provided guidance focusing on three key strategic pillars: developing new treatments with patient-centered urgency, strengthening engagement with U.K. capital markets, and maintaining a disciplined capital allocation approach. PureTech highlighted its promising lead program, deupirfenidone (LYT-100), significant progress in clinical trials, and the potential to deliver long-term value for patients and shareholders. The company also discussed its hub-and-spoke model, exemplified by the success of Karuna Therapeutics, which involved an $18.5 million initial investment leading to a significant financial return. Additionally, PureTech announced plans to appoint up to two new nonexecutive directors to strengthen its board with U.K. capital markets expertise. The interim CEO, Robert Lyne, emphasized their focus on operational discipline and leveraging external capital to fund new entities like Seaport Therapeutics, Gallop Oncology, and Celea Therapeutics, aiming to extend the operational runway well into 2028 with a strong cash position of just under $320 million.

Strong Cash Position and Operational Efficiency

PureTech ended the half year with just under $320 million in cash, cash equivalents, and short-term investments. Operating expenses reduced from $66.7 million in the same period last year to just under $50 million, demonstrating efficient operations.

Successful Financing and Valuation of Seaport Therapeutics

Seaport Therapeutics, a core founded entity of PureTech, raised over $325 million with a $733 million post-money valuation during its Series B round.

Progress in Core Founded Entities

Significant progress in Celea Therapeutics, Gallop Oncology, and Seaport Therapeutics with promising data in IPF and cancer treatments. Notable FDA designations for LYT-200 in Gallop Oncology.

Significant Potential from Cobenfy Royalties

PureTech holds a 2% royalty on Cobenfy sales above $2 billion annually, with potential milestones projecting around $300 million in value based on analyst forecasts.

PureTech Health (PRTC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PRTC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 23, 2026	2025 (Q4)	-1.94 / -	3.6	―	―	―
Aug 28, 2025	2025 (Q2)	-2.04 / -1.90	-1.5	-26.67% (-0.40)	―
Apr 30, 2025	2024 (Q4)	-2.83 / 3.60	-1.5	340.00% (+5.10)	―
Aug 28, 2024	2024 (Q2)	-3.03 / -1.50	-0.9	-66.67% (-0.60)	―
Apr 25, 2024	2023 (Q4)	-3.25 / -1.50	-0.78	-92.31% (-0.72)	―
Aug 29, 2023	2023 (Q2)	-0.03 / -0.90	-1	10.00% (+0.10)	―
Apr 28, 2023	2022 (Q4)	0.34 / -0.78	0.5	-256.00% (-1.28)	―
Aug 25, 2022	2022 (Q2)	-2.75 / -1.00	-2.6	61.54% (+1.60)	―	―
Apr 26, 2022	2021 (Q4)	-2.45 / 0.50	-4.13	112.11% (+4.63)	―	―
Aug 24, 2021	2021 (Q2)	-2.31 / -2.60	4.2	-161.90% (-6.80)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PRTC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 28, 2025	$18.01	$17.35	-3.66%
Apr 30, 2025	$17.50	$17.26	-1.37%
Aug 28, 2024	$25.00	$23.50	-6.00%
Apr 25, 2024	$27.48	$27.86	+1.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PureTech Health (PRTC) report earnings?

PureTech Health (PRTC) is schdueled to report earning on Apr 23, 2026, TBA (Confirmed).

What is PureTech Health (PRTC) earnings time?

PureTech Health (PRTC) earnings time is at Apr 23, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PRTC EPS forecast?

PRTC EPS forecast for the fiscal quarter 2025 (Q4) is -1.94.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing